A Study to Examine Diabetes Control and Patient Reported Outcomes Among Kidney Transplant Recipients with Type 2 Diabetes


About this study

This study aims to measure the percentage of time spent in hyperglycemia in patients on insulin therapy and evaluate diabetes related patient reported outcomes in kidney transplant recipients with type 2 diabetes. It also aimes to evaluate immunosuppression related patient reported outcomes in kidney transplant recipients with type 2 diabetes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with T2DM prior to transplant who are followed in our kidney transplant clinic at Mayo Clinic Rochester
  • Age ≤ 70 at the time of transplant
  • Positive C peptide (>2.0 ng/ml)at any time  and/or clinically verified T2DM
  • Time post transplant 1- 4 years
  • On insulin  ± other antihyperglycemic agents (study group N=15) and on single non-insulin based agent (control group N=15)
  • 2 groups : BMI >35 kg/m2 (N=15) and <35 kg/m2 (N=15)

Exclusion Criteria:

  • Patients on no anti-hyperglycemic treatment
  • Unable to give a consent
  • Non-english speaking, unable to fill the questionnaires

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aleksandra Kukla, M.D.

Open for enrollment

Contact information:

Corey Reid B.S.

(507) 255-0316


More information


Publications are currently not available